ClinicalTrials.gg
CompletedNCT05567601Updated Jun 5, 2025

Doxil/Caelyx BE Study

A Phase 1 interventional study of DOXIL/CAELYX in Ovarian Cancer, AIDS-related Kaposi Sarcoma and Multiple Myeloma, sponsored by Baxter Healthcare Corporation. Completed at 14 sites in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Baxter Healthcare Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing liposomal doxorubicin in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. liposomal doxorubicin · Ovarian Neoplasms.

Enrollment
29th of 42
36 · median 53
Started
2023
with 1 other
Phase 1
11 of 42
none open now
Registered
40th of 42
by date
Lead sponsor
1 of 42
Baxter Healthcare Corporation

Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, this one is the 29th largest by enrollment, is one of 2 that started in 2023, is one of 11 in phase 1, and was the 40th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms as a file.
02

Study summary

The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities. According to the Food and Drug Administration (FDA), two products are considered to be bioequivalent when they are equal in the rate and extent to which the active pharmaceutical ingredient (API) becomes available at the site(s) of drug action. Any abnormalities of the safety endpoints (Clinical Laboratory Test, Electrocardiogram, Left Ventricular Ejection Fraction, Physical Examination) will be captured as Adverse Events.

03

Conditions studied

  • Ovarian Cancer
  • AIDS-related Kaposi Sarcoma
  • Multiple Myeloma
  • Metastatic Breast Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a man or woman aged from 18 to 75 years, inclusive.
  2. Patients with advanced or ovarian or breast cancer, expected to require at least 2 cycles of DOXIL/CAELYX therapy at Screening, are eligible for treatment per this study protocol. This includes:

    1. or cytologically confirmed advanced ovarian cancer failing platinum-based chemotherapy
    2. Histologically or cytologically confirmed breast cancer after failing approved life-prolonging therapies
  3. greater than 6 months based on the clinical evaluation by the investigator at the time of Screening.
  4. (ECOG) Performance status 0 to 2, inclusive.
  5. Recovered from the acute toxicity of any prior treatment (exemptions: alopecia, neuropathy Grade I). All toxicities from prior treatment should return to baseline or Grade I.
  6. Prior doxorubicin (or other anthracyclines) at cumulative dose of ≤ 240 mg/m2 or cumulative epirubicin dose ≤ 720 mg/m2 (calculated using doxorubicin equivalent doses: 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 0.3 mg mitoxantrone = 0.25 mg idarubicin). Patients without any prior anthracycline exposure can also be included.
  7. Adequate liver function as determined by serum total levels ≤ 1.2 mg/dL, and serum (ALT) and aspartate aminotransferase (AST) levels ≤ 2.5 x .
  8. Adequate bone marrow function, as determined by an (ANC) ≥ 1500/mm3 (or ≥ 1.5 x 109/L), a count ≥ 100,000/mm3 (or ≥ 100 x 109/L), and a level ≥ 9 g/dL (or ≥ 90 g/L), in the absence of transfusion requirements or cytokine support for at least 7 days prior to enrolling in the study.
  9. Adequate renal function (mL/min), as determined by multiplying estimated (e-GFR) by the body surface area (BSA) and dividing the value by 1.73 m2.
  10. (LVEF) within normal limits of the institution, as determined by multiple uptake gated acquisition (MUGA) or echocardiography.
  11. Female patients (of ) must use medically acceptable methods of (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patches, intrauterine devices, the double-barrier method, male partner sterilization) before enrollment, throughout the study and for at least 8 months after the last DOXIL/CAELYX infusion.
  12. Male patients must agree to use an adequate contraception method as deemed appropriate by the Investigator and always use condoms when sexually active during the study. Medically acceptable methods of contraception that may be used by the patient and/or his partner include oral contraceptives, contraceptive injections, contraceptive patches, intrauterine devices, the double-barrier method, and surgical sterilization (vasectomy or tubal ligation) for minimally 6 months after the last administration of DOXIL/CAELYX. Sperm donation is not allowed during the study and for minimally 6 months after the last administration of DOXIL/CAELYX.
  13. Negative pregnancy test (urinary or serum beta-human chorionic gonadotropin [β-HCG]) at Screening (applicable to women of childbearing potential) within 7 days prior to starting treatment.
  14. Patients with no history of addiction to any recreational drug or drug dependence or alcohol addiction.
  15. Patients must have signed an form indicating that they understand the purpose and procedures required, and are willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Positive history of known or . Patients with brain metastases can only be enrolled if the following conditions are all met:

    1. Brain metastases have been treated and stable for > 4 weeks (> 2 weeks after SRS/Cyberknife)
    2. No evidence for progression or hemorrhage after treatment
    3. treatment was discontinued at least 2 weeks prior to first administration of DOXIL/CAELYX
    4. Enzyme inducing anti-epileptic drugs were discontinued at least 4 weeks before the first administration of DOXIL/CAELYX
  2. Has a history of reaction to doxorubicin HCl or other components of DOXIL/CAELYX.
  3. Has a history of prior or concomitant that requires other active treatment.
  4. Require any antineoplastic treatment while on the study (including therapy with another agent, radiation therapy, and/or surgical resection).
  5. Any major surgery, radiotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed ≥ 2 weeks prior to the first dose; ≥ 4 weeks for whole brain radiotherapy). Chemotherapy regimens with delayed toxicity within the last 3 weeks (or within the last 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks or 5 half-lives (whichever is shorter).
  6. Use of an drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of DOXIL/CAELYX.
  7. Impaired cardiac function including any of the following conditions within the past 6 months:

    1. Unstable angina
    2. prolongation (QTc > 470 millisecond) or other significant abnormalities
    3. Coronary artery bypass graft surgery
    4. Symptomatic peripheral vascular disease
    5. Myocardial infarction
    6. class II-IV heart failure
    7. Severe uncontrolled ventricular arrhythmias
    8. pericardial disease
    9. Electrocardiographic evidence of acute ischemic or active conduction system abnormalities
    10. Patients with evidence of abnormal cardiac conduction (e.g. bundle branch block or heart block) are eligible if their disease has been stable for the past six months
    11. Severe uncontrolled arrhythmias
  8. Has an infection that is either uncontrolled, clinically important (occurred within 4 weeks prior to first dose of study agent), or requiring current systemic IV treatment.
  9. Patients with active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, P. carinii or other microorganism if under treatment with myelotoxic drugs
  10. Patient has received a diagnosis of COVID-19 (diagnosis ≤ 2 months prior and/or symptoms have not resolved).
  11. A patient with uncontrolled concurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or psychiatric illness/social situation that may potentially impair the patient's compliance with study procedures.
  12. Concomitant use of strong inhibitors (such as clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, nefazodone, ritonavir, telithromycin and verapamil) and strong CYP3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin and St John's wort) from at least 4 weeks before the first dose of DOXIL/CAELYX in Cycle 1 and until after completion of all PK sampling on Day 26 of Cycle 2.
  13. Has any condition that, in the opinion of the Investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments.
  14. Is a woman who is pregnant, or breast-feeding, or planning to become pregnant within 8 months or is a man who plans to father a child while enrolled in this study or within 6 months after the last dose of study drug.
  15. Is an employee of the Investigator or study site, with direct involvement in the proposed study or other studies under the direction of that Investigator or study site, as well as family members of the employees or the Investigator.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Current Manufacturing Site

    On Day 1 of Cycle 1 of the open-label treatment phase, patients will be randomized to receive drug from either current or new manufacturing site, and then after 28 days cross-over to the drug produced from the other manufacturing site in Cycle 2.

    Drug: DOXIL/CAELYX

  • Experimental
    New Manufacturing Site

    On Day 1 of Cycle 1 of the open-label treatment phase, patients will be randomized to receive drug from either current or new manufacturing site, and then after 28 days cross-over to the drug produced from the other manufacturing site in Cycle 2.

    Drug: DOXIL/CAELYX

Interventions

  • DrugDOXIL/CAELYX

    Drug page: Liposomal doxorubicin

    40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein

    Also known as: doxorubicin hydrochloride liposome injection 2 mg/mL

06

What researchers measure

Primary outcomes

  1. Cmax based on encapsulated doxorubicin in patients

    Cmax=maximum observed plasma concentration.

    Time frame: Day 1 (Cycle 1) and Day 28 (Cycle 2) at 15 minutes (min) prior to dosing as a baseline measurement and at 15 min, 30 min, 1 hour (h), 1 h 30 min, 1 h 35 min, 1h 45 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, 48 h, 96 h, 168 h, 240 h, 336 h, 504 h post-dosing

  2. AUC0-t based on encapsulated doxorubicin in patients

    AUC0-t=area under the plasma concentration-time curve from time 0 to time t (interchangeable with AUC0-last).

    Time frame: Day 1 (Cycle 1) and Day 28 (Cycle 2) at 15 minutes (min) prior to dosing as a baseline measurement and at 15 min, 30 min, 1 hour (h), 1 h 30 min, 1 h 35 min, 1h 45 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, 48 h, 96 h, 168 h, 240 h, 336 h, 504 h post-dosing

  3. AUC0-∞ based on encapsulated doxorubicin in patients

    AUC0-∞=area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUClast and Clast/λz, in which Clast is the last observed quantifiable concentration. The reference and the test products will be considered bioequivalent if the three 90% CIs for encapsulated doxorubicin fall within (0.80, 1.25).

    Time frame: Day 1 (Cycle 1) and Day 28 (Cycle 2) at 15 minutes (min) prior to dosing as a baseline measurement and at 15 min, 30 min, 1 hour (h), 1 h 30 min, 1 h 35 min, 1h 45 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, 48 h, 96 h, 168 h, 240 h, 336 h, 504 h post-dosing

Secondary outcomes

  1. Cmax based on total doxorubicin in patients

    Cmax=maximum observed plasma concentration. The same analyses as described for encapsulated doxorubicin will be performed for total doxorubicin.If the primary endpoint results in BE, then the secondary endpoints will be tested for BE.

    Time frame: Day 1 (Cycle 1) and Day 28 (Cycle 2) at 15 minutes (min) prior to dosing as a baseline measurement and at 15 min, 30 min, 1 hour (h), 1 h 30 min, 1 h 35 min, 1h 45 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, 48 h, 96 h, 168 h, 240 h, 336 h, 504 h post-dosing

  2. AUC0-t based on total doxorubicin in patients

    AUC0-t=area under the plasma concentration-time curve from time 0 to time t (interchangeable with AUC0-last). The same analyses as described for encapsulated doxorubicin will be performed for total doxorubicin.If the primary endpoint results in BE, then the secondary endpoints will be tested for BE.

    Time frame: Day 1 (Cycle 1) and Day 28 (Cycle 2) at 15 minutes (min) prior to dosing as a baseline measurement and at 15 min, 30 min, 1 hour (h), 1 h 30 min, 1 h 35 min, 1h 45 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, 48 h, 96 h, 168 h, 240 h, 336 h, 504 h post-dosing

  3. AUC0-∞ based on total doxorubicin in patients

    AUC0-∞=area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUClast and Clast/λz, in which Clast is the last observed quantifiable concentration. The same analyses as described for encapsulated doxorubicin will be performed for total doxorubicin.If the primary endpoint results in BE, then the secondary endpoints will be tested for BE.

    Time frame: Day 1 (Cycle 1) and Day 28 (Cycle 2) at 15 minutes (min) prior to dosing as a baseline measurement and at 15 min, 30 min, 1 hour (h), 1 h 30 min, 1 h 35 min, 1h 45 min, 2 h, 3 h, 4 h, 6 h, 8 h, 24 h, 48 h, 96 h, 168 h, 240 h, 336 h, 504 h post-dosing

  4. Tumor response assessment

    By computed tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis (plus other regions as required for specific tumor types) and other established assessments of tumor burden if CT/MRI imaging is insufficient for the individual patient. Tumor response will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    Time frame: Screening (28 days before Day 1) and between Day 46-56 (10 days before Cycle 3)

07

Study locations

14 sites
  • HCG City Cancer Centre
    Vijayawada, Andhra Pradesh 520002, India
  • Omega Hospital
    Visakhapatnam, Andhra Pradesh 530040, India
  • Sanjeevani CBCC USA Cancer Hospital
    Raipur, Chhattisgarh 492001, India
  • Unique Hospital Multispeciality & Research Institute
    Surat, Gujarat 395017, India
  • Kailash Cancer Hospital and Research Centre
    Goraj, Gurajat 391760, India
  • Medstar Speciality
    Bangalore, Karnataka 560092, India
  • Oncoville Cancer Hospital & Research Centre
    Bengaluru, Karnataka 560072, India
  • Sparsh Hospital & Critical Care Ltd.
    Bhubaneshwar, Khndha-Orissa 751007, India
  • Indrayani Hospital
    Pune, Maharashtra 412105, India
  • Erode Cancer Centre
    Erode, Tamil Nadu 638012, India
  • Swami Har Shankaranand
    Varanasi, Uttar Pradesh 221005, India
  • Sujan Surgical Cancer Hospital and Amravati Cancer Foundation
    Amravati, 444605, India
  • Kolhapur Cancer Center
    Kolhapur, 416234, India
  • HCG Manavata Cancer Centre
    Nashik, 422002, India
08

References and documents

Individual participant data

Plan to share: Yes — Baxter is committed to sharing clinical trial data with external medical experts and scientific researchers in the interest of advancing public health. As such, Baxter will supply anonymized Individual Patient Datasets (IPD) and supporting documents (synopsis of clinical study reports, protocol and SAP's)

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Upon approval of a legitimate research request.

Access criteria: Research requests will be reviewed by qualified medical and scientific experts within the company. If Baxter agrees to the release of clinical data for research purposes, the requestor will be required to sign a data sharing agreement (DSA) in order to ensure protection of patient confidentiality and any intellectual property rights of Baxter prior to the release of any data.

Data sharing details ↗ · www.baxter.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jun 2024, 6 months.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 6 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 5, 2022
StartActual
Dec 16, 2023
Primary completionActual
Jun 21, 2024
CompletionActual
Jun 21, 2024
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05567601
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Dec 16, 2023
Primary completion
Jun 21, 2024
Completion
Jun 21, 2024
Last update
Jun 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion